Allergan PLC. (NYSE:AGN) Chairman Brent L. Saunders purchased 4,600 shares of the stock in a transaction that occurred on Wednesday, December 6th. The shares were purchased at an average price of $164.74 per share, with a total value of $757,804.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Allergan PLC. (AGN) traded down $2.62 during midday trading on Wednesday, hitting $164.28. 7,569,700 shares of the stock were exchanged, compared to its average volume of 2,931,912. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 1.18. The stock has a market cap of $54,640.00, a P/E ratio of 10.82, a PEG ratio of 1.12 and a beta of 1.11. Allergan PLC. has a 12-month low of $160.07 and a 12-month high of $256.80.

Allergan (NYSE:AGN) last announced its quarterly earnings results on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.06 by $0.09. The firm had revenue of $4.03 billion for the quarter, compared to the consensus estimate of $4.04 billion. Allergan had a negative net margin of 47.27% and a positive return on equity of 8.00%. The business’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter last year, the firm posted $3.32 EPS. equities research analysts forecast that Allergan PLC. will post 16.28 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Stockholders of record on Friday, November 17th will be issued a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.70%. The ex-dividend date of this dividend is Thursday, November 16th. Allergan’s payout ratio is presently -12.39%.

Allergan announced that its Board of Directors has initiated a share repurchase plan on Monday, September 25th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire up to 2.8% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s leadership believes its stock is undervalued.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Howard Hughes Medical Institute bought a new position in shares of Allergan in the 2nd quarter worth approximately $103,000. Cable Hill Partners LLC lifted its stake in shares of Allergan by 255.2% in the 3rd quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock worth $106,000 after purchasing an additional 370 shares during the period. Rockefeller Financial Services Inc. lifted its stake in shares of Allergan by 283.7% in the 3rd quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock worth $111,000 after purchasing an additional 400 shares during the period. Jacobi Capital Management LLC lifted its stake in shares of Allergan by 4.9% in the 1st quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after purchasing an additional 22 shares during the period. Finally, Massey Quick & Co. LLC lifted its stake in shares of Allergan by 334.8% in the 2nd quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock worth $122,000 after purchasing an additional 385 shares during the period. 81.34% of the stock is currently owned by hedge funds and other institutional investors.

AGN has been the subject of several research reports. Wells Fargo & Company restated an “outperform” rating and issued a $280.00 price objective (up from $270.00) on shares of Allergan in a report on Wednesday, August 9th. BidaskClub downgraded shares of Allergan from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Deutsche Bank reissued a “buy” rating and set a $278.00 price objective (up from $273.00) on shares of Allergan in a research report on Wednesday, August 9th. UBS reissued an “outperform” rating and set a $275.00 price objective on shares of Allergan in a research report on Wednesday, August 9th. Finally, Argus reissued a “buy” rating and set a $280.00 price objective on shares of Allergan in a research report on Monday, August 14th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $244.47.

ILLEGAL ACTIVITY NOTICE: “Allergan PLC. (AGN) Chairman Acquires $757,804.00 in Stock” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/12/06/allergan-plc-agn-chairman-acquires-757804-00-in-stock.html.

Allergan Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.